- Home
- VATE vs RFL Comparison
VATE vs RFL Comparison
Compare VATE & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VATE | RFL |
|---|---|---|
| Founded | 1994 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Real Estate |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.2M | 63.5M |
| IPO Year | 1996 | 2017 |
Fundamental Metrics
Financial Performance| Metric | VATE | RFL |
|---|---|---|
| Price | $13.09 | $1.33 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 54.3K | ★ 71.8K |
| Earning Date | 05-14-2026 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,246,000,000.00 | $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 12.55 | ★ 43.96 |
| 52 Week Low | $3.75 | $1.12 |
| 52 Week High | $13.46 | $3.19 |
Technical Indicators
Market Signals| Indicator | VATE | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 62.85 | 55.35 |
| Support Level | $4.47 | $1.30 |
| Resistance Level | $13.40 | $1.38 |
| Average True Range (ATR) | 1.02 | 0.08 |
| MACD | -0.14 | 0.00 |
| Stochastic Oscillator | 86.24 | 61.17 |
Price Performance
Historical ComparisonAbout VATE INNOVATE Corp.
Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments. Its segments include Infrastructure, Life Sciences and Spectrum, and Other segment. Through its subsidiaries it provides fully integrated structural and steel construction services; supports healthcare and biotechnology product development; and operates Over-The-Air (OTA) broadcasting stations across the United States (U.S.) including Puerto Rico.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.